| Authors: |
Shub L; Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.; Department of Bioengineering and Therapeutic Sciences, Bakar Health Sciences Institute; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, California 94158, United States., Korczynska M; Medicine Design, Pfizer Research & Development, Cambridge, Massachusetts 02139, United States., Muir DF; Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.; Department of Bioengineering and Therapeutic Sciences, Bakar Health Sciences Institute; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, California 94158, United States., Lin FY; Medicine Design, Pfizer Research & Development, Cambridge, Massachusetts 02139, United States., Hall BW; Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.; Department of Bioengineering and Therapeutic Sciences, Bakar Health Sciences Institute; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, California 94158, United States., Mathiowetz AM; Medicine Design, Pfizer Research & Development, Cambridge, Massachusetts 02139, United States., Keiser MJ; Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.; Department of Bioengineering and Therapeutic Sciences, Bakar Health Sciences Institute; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, California 94158, United States. |
